37.25p+0.00 (+0.00%)30 Jun 2022, 15:39
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Rua Life Sciences PLC Fundamentals

Company NameRua Life Sciences PLCLast Updated2022-06-30
IndustryMedical DevicesSectorHealthcare
Shares in Issue22.185 mMarket Cap£8.26 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.08EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0425Debt Equity Ratio0.0427
Asset Equity Ratio1.2233Cash Equity Ratio0.6558
Quick Ratio5.9315Current Ratio6.12
Price To Book Value1.1378ROCE0

Rua Life Sciences PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Rua Life Sciences PLC Company Financials

Tangible Assets£1.95 m£5,000.00£1,000.00
Intangible Assets£875,000.00£255,000.00£448,000.00
Total Fixed Assets£2.83 m£260,000.00£449,000.00
Cash & Equivalents£6.29 m£1.01 m£2.41 m
Other Assets000
Total Assets£10.15 m£2.49 m£3.10 m
Creditors within 1 year£1.10 m£219,000.00£99,000.00
Creditors after 1 year£550,000.0000
Other Liabilities000
Total Liabilities£1.65 m£219,000.00£99,000.00
Net assets£8.51 m£2.27 m£3.00 m
Called up share capital£12.95 m£12.57 m£12.57 m
Share Premium£11.73 m£4.55 m£4.55 m
Profit / Loss-£1.59 m-£897,000.00-£609,000.00
Other Equity£8.51 m£2.27 m£3.00 m
Preference & Minorities000
Total Capital Employed£8.51 m£2.27 m£3.00 m
Debt Ratio£0.0400
Assets / Equity1.22331.22331.2233
Cash / Equity0.65580.65580.6558
Cash Flow202120202019
Cash from operating activities-£1.41 m-£438,000.00-£429,000.00
Cashflow before financing£5.27 m-£438,000.00£2.12 m
Increase in Cash£4.32 m-£436,000.00£1.99 m
Turnover£1.53 m£489,000.00£463,000.00
Cost of sales£276,000.0000
Gross Profit£1.25 m£489,000.000
Operating Profit-£1.55 m-£941,000.00-£638,000.00
Pre-Tax profit-£1.59 m-£897,000.00-£609,000.00

Rua Life Sciences PLC Company Background

ActivitiesRUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's only operating segment; exploiting the value of its IP and know-how. Geographically, it derives most of the revenue from the USA and has a presence in Europe and the Rest of the world. It has developed biostable, implantable polymers, including technology such as Elast-Eon, Elast-Eon Carbonate Silicone, and Elast-Eon Reaction Injection Molding (RIM) technology. Also, the company has developed a range of large bore vascular grafts. The company earns its revenues in the form of royalties and license fees.
Latest Interim Date16 Dec 2021
Latest Fiscal Year End Date15 Jul 2022

Rua Life Sciences PLC Directors

2020-12-11Mr. James Gordon Wright Non-Executive Director
2013-12-03Mr. Francis Patrick Maguire Executive Director,Chief Executive
2012-12-31Mr. Jonathan Peter PitherNon-Executive Director
2016-10-31Mr. Edward Eddie McDaid Executive Director,Chief Executive Officer
2021-07-28Mr. William Donald Brown Executive Director,Chairman
2011-10-21Dr. Stuart Bernard Rollason Non-Executive Director
2015-06-01Mr. Roy Walter Mitchell Non-Executive Director,Finance Director
2021-07-28Mr. John McKenna Executive Director,Director of Clinical Marketing
2021-07-28Mr. John Louis Ely Non-Executive Director
2021-07-28Mr. Geoffrey Alan Berg Non-Executive Director
2021-08-10Mr. David Muir Richmond Executive Director,Chief Executive Officer
2021-02-05Dr. Caroline StrettonExecutive Director,Managing Director

Rua Life Sciences PLC Contact Details

Company NameRUA Life Sciences PLC
Addressc/o Kergan Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ

Rua Life Sciences PLC Advisors

RegistrarEquiniti Limited
Phone+44 2072200500
Fax+44 2076001659
AuditorGrant Thornton UK LLP
Phone(0116) 247 1234
Fax(0116) 247 1434
SolicitorDAC Beachcroft LLP
Phone+44 2072421011
Fax+44 2078316630
SolicitorBrodies LLP
Phone(0131) 228 3777
Fax(0131) 228 3878
BankBank of Scotland
Nominated AdviserFinnCap
Phone+44 2072200500
Fax+44 2076001659